Monday, October 21, 2013

Top 10 Medical Innovations for 2014: Hepatitis C Drug Sofosbuvir Number 4

Cleveland Clinic News Wire

No. 4 Innovation: A Breakthrough for Hepatitis C (Video)
Better treatment in less time

Cleveland Clinic asked more than 100 of its top experts about the innovations set to reshape healthcare in the coming year. These are their answers — the Top 10 Innovations for 2014.

For the 4 million people in the United States with a hepatitis C infection, treatment options have improved greatly in the past three years.

Until 2011, there were no proven medicines for patients who didn’t respond to traditional therapy for this liver disease. That year, two new drugs— telaprevir and boceprevir—made Cleveland Clinic’s top 10 innovations list and changed the prospects for patients in need. This year, yet another promising option makes the list: sofosbuvir, the first all-oral hepatitis C treatment.

Shorter, safer and easier to tolerate
Sofosbuvir is moving through the final stages of FDA approval. Its promise includes the highest cure rates ever, reduced treatment time and fewer side effects.

Its promise includes the highest cure rates ever, reduced treatment time and fewer side effects.
This medication would be the first of a new generation of hepatitis C drugs called direct-acting antivirals (DAA). DAAs can improve what for many has been a very difficult treatment regimen — one that can take up to 48 weeks and requires injections of interferon, a drug that is difficult to tolerate.

More important, DAAs can improve treatment response rates to 90 percent or higher. Sofosbuvir — and other DAAs in the pipeline — also are more tolerable and safer.

Even better, they reduce the treatment length to 12 weeks.

Source - Cleveland Clinic

Upcoming Review
FDA Antiviral Drugs Advisory Committee.
October 25, 2013 Sofosbuvir Review

Viral Levels Reduced in Patients with Chronic Hep C Infections Treated with Interferon-Free Regimen
The JAMA Report

This study was published in the August issue of Journal of the American Medical Association (JAMA) which tested genotype 1 patients who have characteristics associated with poor response to other treatment using Sofosbuvir/Ribavirin without interferon.
Video Source

No comments:

Post a Comment